+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

  • ID: 3797420
  • Report
  • 806 pages
  • Datamonitor Healthcare
1 of 2

Disease Overview
Multiple myelomas is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age at diagnosis has an impact on patient outcome, especially in terms of the treatment options available. Most patients will receive at least three lines of treatment, and eligible patients will receive stem cell transplantation.

Market Snapshot

  • Generic erosion of Revlimid will be a major growth resistor in the multiple myeloma market.
  • Alongside SCT, several triplet combination regimens are used as the standard treatment for patients across all lines of therapy.
  • The incident population is forecast to undergo a substantial 39%increase from 58,200 cases in 2017 to 81,050 in 2037.
  • A number of leading multiple myeloma drugs will soon face generic competition.
  • Pipeline candidates will use novel mechanisms of action as distinguishing factors in an increasingly crowded market.
  • Multiple myeloma drugs will enjoy reimbursement by US payers for the foreseeable future, while novel combinations will spur risk sharing in Europe.
Note: Product cover images may vary from those shown
2 of 2

FORECAST: MULTIPLE MYELOMA (Published on 09 August 2018)
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Darzalex
Product Profile: Empliciti
Product Profile: Farydak
Product Profile: Kyprolis
Product Profile: Ninlaro
Product Profile: Pomalyst
Product Profile: Revlimid
Product Profile: Thalomid
Product Profile: Treanda
Product Profile: Velcade
Product Profile (Late Stage): Venclexta
Product Profile (Late Stage): Ygalo
Product Profile (Late Stage): Bb2121
Product Profile (Late Stage): Isatuximab
Product Profile (Late Stage): Selinexor

TREATMENT: MULTIPLE MYELOMA (Published on 26 October 2018)
Overview
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends

EPIDEMIOLOGY: MULTIPLE MYELOMA (Published on 08 August 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: MULTIPLE MYELOMA (Published on 09 August 2018)
Overview
Product Overview
Product Profile: Darzalex
Product Profile: Empliciti
Product Profile: Farydak
Product Profile: Kyprolis
Product Profile: Ninlaro
Product Profile: Pomalyst
Product Profile: Revlimid
Product Profile: Thalomid
Product Profile: Treanda
Product Profile: Velcade

MULTIPLE MYELOMA PRICING, REIMBURSEMENT, AND ACCESS (Published on 12 May 2016)
Overview
Executive Summary
Market Context
Global Payer And Key Opinion Leader Insights
US Pricing
US Payer And Key Opinion Leader Insights
US Reimbursement
Japan
Pricing In The Five Major Eu Markets
Five Major Eu Markets Payer And Key Opinion Leader Insights
France
Germany
Italy
Spain
UK
Appendix

PIPELINE: MULTIPLE MYELOMA (Published on 09 August 2018)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Venclexta
Product Profile (Late Stage): Ygalo
Product Profile (Late Stage): Bb2121
Product Profile (Late Stage): Isatuximab
Product Profile (Late Stage): Selinexor

Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll